Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-07-03 Share Issue/Capital Cha…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA – End of stabilisation
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses the 'End of stabilisation' following an Initial Public Offering (IPO). It details the purchase of shares (133,176 shares) as part of stabilisation activities and the subsequent sale (exercise of put option) of these shares to specific anchor investors (Gjelsten Holding AS, Canica AS, etc.). Stabilisation activities in the context of an IPO are related to managing the share price immediately after listing, which is a financing/capital market activity. This content is directly related to capital structure changes and fundraising events, making 'Capital/Financing Update' (CAP) the most appropriate classification, as it details the conclusion of post-IPO market support mechanisms. It is not an ER (only stabilization details, not full results), not a 10-K (not annual report), and not a DIRS (not director dealing). It is a specific announcement related to the capital raising process.
2019-07-03 English
Ultimovacs ASA - European patent approval for UV1
Regulatory Filings Classification · 100% confidence The document is a short announcement from Ultimovacs ASA regarding the granting of a European patent for their product UV1. It details the patent number, coverage period, and lists other jurisdictions where patents have been granted. This type of announcement, which is not a comprehensive financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a director's dealing (DIRS), nor a specific regulatory filing like a proxy statement (DEF 14A/PSI), does not fit neatly into the primary financial categories. Since it is a specific, non-financial regulatory/legal update concerning intellectual property, it is best classified under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'Legal Proceedings Report' (LTR) if patent grants are grouped there, but RNS is the standard fallback for specific, non-financial corporate news that isn't covered elsewhere. Given the options, RNS is the most appropriate general regulatory announcement category for a patent grant notice.
2019-06-25 English
Ultimovacs ASA - Share Option Program
Remuneration Information Classification · 99% confidence The document explicitly details the issuance of share options to employees and primary insiders under an approved incentive program. This involves changes to the capital structure through the granting of rights to acquire shares, and it specifically reports the transactions of directors and executives (insider dealing/granting). While it involves capital structure changes (CAP) and insider transactions (DIRS), the core subject is the granting of options to management/directors as part of compensation/incentive, which often falls under Director's Dealing (DIRS) if it's a report of insider transactions, or Capital/Financing Update (CAP) if it's a broad issuance. Given the detailed breakdown of grants to specific named primary insiders (CEO, CFO, etc.), the most precise classification is Director's Dealing (DIRS), as these reports track executive transactions, even if they are options grants rather than open-market purchases. However, since this is a formal announcement of an employee share option program and the granting of options, it is fundamentally a capital structure event related to employee incentives. Comparing DIRS (personal share transactions by directors) vs CAP (fundraising, financing activities, or capital structure changes), this is a direct capital structure change via option issuance. Since the document focuses heavily on the mechanics of the option grant and the resulting holdings of insiders, DIRS is a strong candidate, but CAP covers the issuance of options/shares under incentive plans well. Let's re-evaluate the definitions. DIRS is for 'personal share transactions by company directors and executives (insider trades)'. This is a grant, which is a transaction. CAP is for 'Updates on company fundraising, financing activities, or capital structure changes'. Issuing options changes the capital structure. Given the detailed listing of insider grants, DIRS is highly relevant. However, if we look at the structure, it's an announcement of a program execution. Since it details specific grants to insiders, DIRS is the most specific fit for tracking executive equity changes. If it were purely about the program structure without insider specifics, CAP might fit better. Given the explicit listing of insider grants, DIRS is chosen.
2019-06-03 English
Oslo Børs - Ultimovacs ASA - Nytt selskap til notering / New security will be listed 03.06.2019
Regulatory Filings Classification · 95% confidence The document is a short announcement from Oslo Børs regarding the listing of a new security, Ultimovacs ASA, on June 3, 2019. It provides details like the name, ticker (ULTIMO), ISIN, instrument type (Share), and the number of shares being listed. This is a formal regulatory announcement concerning the admission of a security to trading, which does not fit the specific categories like 10-K, ER, or DIV. Given its nature as a general regulatory notice about a corporate event (listing), and lacking a more specific category, it best fits the 'Regulatory Filings' (RNS) fallback category, as it is a standard exchange announcement.
2019-06-03 Norwegian
Ultimovacs ASA – Stabilisation notice
Share Issue/Capital Change Classification · 99% confidence The document is titled "Ultimovacs ASA – Stabilisation notice" and explicitly discusses stabilization activities following an Initial Public Offering (IPO). Stabilization activities involve the Stabilisation Manager buying shares to support the market price, often using options granted by existing shareholders. This activity is directly related to the issuance and offering of securities and capital structure changes surrounding the IPO. While it touches upon the IPO process, it is a specific regulatory notice concerning market support mechanisms post-offering, rather than the main prospectus or the final capital change announcement itself. It is most closely related to financing activities and capital structure adjustments. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as stabilization is a mechanism used during or immediately following a financing event (the IPO). It is not a general regulatory filing (RNS) because it describes a specific, defined corporate action related to capital raising.
2019-06-03 English
Oslo Børs - Ultimovacs ASA - Nytt selskap til notering / New security will be listed 03.06.2019
Delisting Announcement Classification · 99% confidence The document is a short announcement from Oslo Børs regarding the listing of a new security, Ultimovacs ASA, on June 3, 2019. It provides details like the name, ticker (ULTIMO), ISIN, instrument type (Share), and the number of shares being listed. This is a formal regulatory announcement concerning the admission of a security to trading, which does not fit the specific categories like 10-K, ER, or DIV. Given its nature as a general regulatory notice about a corporate event (listing), and lacking a more specific category, it best fits the 'Regulatory Filings' (RNS) fallback category, as it is a standard exchange announcement.
2019-05-31 Norwegian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.